{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T17:55:21Z","timestamp":1793987721496,"version":"4.8.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,3,6]],"date-time":"2018-03-06T00:00:00Z","timestamp":1520294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,3,6]],"date-time":"2018-03-06T00:00:00Z","timestamp":1520294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The Ministry of Health, Labour, and Welfare of Japan"},{"name":"The Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research","award":["15K09246"],"award-info":[{"award-number":["15K09246"]}]},{"name":"The Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research","award":["16K09834"],"award-info":[{"award-number":["16K09834"]}]},{"name":"The Japanese Association for Complement Research"},{"name":"The Takeda Scientific Foundation"},{"name":"The Practical Research Project for Rare\/Intractable Diseases from Japan Agency for Medical Research and Development, AMED","award":["17ek0109254h0001"],"award-info":[{"award-number":["17ek0109254h0001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2018,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Atypical hemolytic uremic syndrome (aHUS) is caused by complement overactivation, and its presentation and prognosis differ according to the underlying molecular defects. The aim of this study was to characterize the genetic backgrounds of aHUS patients in Japan and to elucidate the associations between their genetic backgrounds, clinical findings, and outcomes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We conducted a nationwide epidemiological survey of clinically diagnosed aHUS patients and examined 118 patients enrolled from 1998 to 2016 in Japan. We screened variants of seven genes related to complement and coagulation, as well as positivity for anti-CFH antibodies, and assessed clinical manifestations, laboratory findings, and clinical course.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The most frequent genetic abnormalities were in <jats:italic>C3<\/jats:italic> (31%) and the frequency of <jats:italic>CFH<\/jats:italic> variants was relatively low (10%) compared to Western countries. The predominant variant in this cohort was <jats:italic>C3 p.I1157T<\/jats:italic> (23%), which was related to favorable outcomes despite frequent relapses. A total of 72% of patients received plasma therapy, while 42% were treated with eculizumab. The prognosis of Japanese aHUS patients was relatively favorable, with a total mortality rate of 5.4% and a renal mortality rate of 15%.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The common occurrence of genotype <jats:italic>C3<\/jats:italic>, especially the <jats:italic>p.I1157T<\/jats:italic> variant was the characteristic of the genetic backgrounds of Japanese aHUS patients that differed from those of Caucasian patients. In addition, the favorable prognosis of patients with the unique <jats:italic>C3 p.I1157T<\/jats:italic> variant indicates that understanding the clinical characteristics of individual gene alterations is important for predicting prognosis and determining therapeutic strategies in aHUS.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s10157-018-1549-3","type":"journal-article","created":{"date-parts":[[2018,3,6]],"date-time":"2018-03-06T03:56:56Z","timestamp":1520308616000},"page":"1088-1099","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Clinical characteristics and genetic backgrounds of Japanese patients with atypical hemolytic uremic syndrome"],"prefix":"10.1007","volume":"22","author":[{"given":"Madoka","family":"Fujisawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Usui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munenori","family":"Takata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumiko","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Kokame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Fujimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Miyata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaomi","family":"Nangaku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,6]]},"reference":[{"issue":"17","key":"1549_CR1","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1056\/NEJMra0902814","volume":"361","author":"M Noris","year":"2009","unstructured":"Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med. 2009;361(17):1676\u201387.","journal-title":"N Engl J Med"},{"issue":"10","key":"1549_CR2","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.2215\/CJN.02210310","volume":"5","author":"M Noris","year":"2010","unstructured":"Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010;5(10):1844\u201359.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"1549_CR3","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s12185-014-1655-2","volume":"100","author":"T Matsumoto","year":"2014","unstructured":"Matsumoto T, Fan X, Ishikawa E, Ito M, Amano K, Toyoda H, et al. Analysis of patients with atypical hemolytic uremic syndrome treated at the Mie University Hospital: concentration of C3 p.I1157T mutation. Int J Hematol. 2014;100(5):437\u201342.","journal-title":"Int J Hematol"},{"issue":"5","key":"1549_CR4","doi-asserted-by":"publisher","first-page":"e0124655","DOI":"10.1371\/journal.pone.0124655","volume":"10","author":"Y Yoshida","year":"2015","unstructured":"Yoshida Y, Miyata T, Matsumoto M, Shirotani-Ikejima H, Uchida Y, Ohyama Y, et al. A novel quantitative hemolytic assay coupled with restriction fragment length polymorphisms analysis enabled early diagnosis of atypical hemolytic uremic syndrome and identified unique predisposing mutations in Japan. PLoS One. 2015;10(5):e0124655.","journal-title":"PLoS One"},{"issue":"4","key":"1549_CR5","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1007\/s10157-016-1276-6","volume":"20","author":"H Kato","year":"2016","unstructured":"Kato H, Nangaku M, Hataya H, Sawai T, Ashida A, Fujimaru R, et al. Clinical guides for atypical hemolytic uremic syndrome in Japan. Clin Exp Nephrol. 2016;20(4):536\u201343.","journal-title":"Clin Exp Nephrol"},{"issue":"2","key":"1549_CR6","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.molimm.2012.12.006","volume":"54","author":"X Fan","year":"2013","unstructured":"Fan X, Yoshida Y, Honda S, Matsumoto M, Sawada Y, Hattori M, et al. Analysis of genetic and predisposing factors in Japanese patients with atypical hemolytic uremic syndrome. Mol Immunol. 2013;54(2):238\u201346.","journal-title":"Mol Immunol"},{"key":"1549_CR7","first-page":"862","volume":"4","author":"T Miyata","year":"2015","unstructured":"Miyata T, Uchida Y, Ohta T, Urayama K, Yoshida Y, Fujimura Y. Atypical haemolytic uraemic syndrome in a Japanese patient with DGKE genetic mutations. Thromb Haemost. 2015;4:862\u20133","journal-title":"Thromb Haemost"},{"key":"1549_CR8","first-page":"265","volume":"49","author":"N Kobayashi","year":"1983","unstructured":"Kobayashi N, Maekawa T, Takada M, Tanaka H, Gonmori H. Criteria for diagnosis of DIC based on the analysis of clinical and laboratory findings in 345 DIC patients collected by the Research Committee on DIC in Japan. Bibl Haematol. 1983;49:265\u201375.","journal-title":"Bibl Haematol"},{"issue":"4","key":"1549_CR9","doi-asserted-by":"publisher","first-page":"554","DOI":"10.2215\/CJN.04760512","volume":"8","author":"V Fremeaux-Bacchi","year":"2013","unstructured":"Fremeaux-Bacchi V, Fakhouri F, Garnier A, Bienaim\u00e9 F, Dragon-Durey MA, Ngo S, et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol. 2013;8(4):554\u201362.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"1549_CR10","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1172\/JCI16651","volume":"111","author":"T Manuelian","year":"2003","unstructured":"Manuelian T, Hellwage J, Meri S, Caprioli J, Noris M, Heinen S, et al. Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. J Clin Investig. 2003;111(8):1181\u201390.","journal-title":"J Clin Investig"},{"issue":"7","key":"1549_CR11","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1681\/ASN.2005101051","volume":"17","author":"V Fremeaux-Bacchi","year":"2006","unstructured":"Fremeaux-Bacchi V, Moulton EA, Kavanagh D, Dragon-Durey MA, Blouin J, Caudy A, et al. Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2006;17(7):2017\u201325.","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"1549_CR12","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/ng.2590","volume":"45","author":"M Lemaire","year":"2013","unstructured":"Lemaire M, Fr\u00e9meaux-Bacchi V, Schaefer F, Choi M, Tang WH, Le Quintrec M, et al. Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat Genet. 2013;45(5):531\u20136.","journal-title":"Nat Genet"},{"issue":"9","key":"1549_CR13","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.2215\/CJN.01640214","volume":"9","author":"D S\u00e1nchez Chinchilla","year":"2014","unstructured":"S\u00e1nchez Chinchilla D, Pinto S, Hoppe B, Adragna M, Lopez L, Justa Roldan ML, et al. Complement mutations in diacylglycerol kinase-\u03b5-associated atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol. 2014;9(9):1611\u20139.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"1549_CR14","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s00467-014-2975-4","volume":"30","author":"T Ohta","year":"2015","unstructured":"Ohta T, Urayama K, Tada Y, Furue T, Imai S, Matsubara K, et al. Eculizumab in the treatment of atypical hemolytic uremic syndrome in an infant leads to cessation of peritoneal dialysis and improvement of severe hypertension. Pediatr Nephrol. 2015;30(4):603\u20138.","journal-title":"Pediatr Nephrol"},{"issue":"3","key":"1549_CR15","doi-asserted-by":"publisher","first-page":"e137","DOI":"10.1097\/MPH.0000000000000505","volume":"38","author":"H Toyoda","year":"2016","unstructured":"Toyoda H, Wada H, Miyata T, Amano K, Kihira K, Iwamoto S, et al. Disease recurrence after early discontinuation of eculizumab in a patient with atypical hemolytic uremic syndrome with complement C3 I1157T mutation. J Pediatr Hematol Oncol. 2016;38(3):e137\u20139.","journal-title":"J Pediatr Hematol Oncol"},{"issue":"6","key":"1549_CR16","doi-asserted-by":"publisher","first-page":"E1445","DOI":"10.1002\/humu.21256","volume":"31","author":"TK Maga","year":"2010","unstructured":"Maga TK, Nishimura CJ, Weaver AE, Frees KL, Smith RJ. Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome. Hum Mutat. 2010;31(6):E1445\u201360.","journal-title":"Hum Mutat"},{"issue":"3","key":"1549_CR17","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1111\/ped.12549","volume":"57","author":"JM Lee","year":"2015","unstructured":"Lee JM, Park YS, Lee JH, Park SJ, Shin JI, Park YH, et al. Atypical hemolytic uremic syndrome: Korean pediatric series. Pediatr Int. 2015;57(3):431\u20138.","journal-title":"Pediatr Int"},{"issue":"3","key":"1549_CR18","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1159\/000445127","volume":"43","author":"T Zhang","year":"2016","unstructured":"Zhang T, Lu J, Liang S, Chen D, Zhang H, Zeng C, et al. Comprehensive analysis of complement genes in patients with atypical hemolytic uremic syndrome. Am J Nephrol. 2016;43(3):160\u20139.","journal-title":"Am J Nephrol"},{"issue":"3 Pt 2","key":"1549_CR19","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/j.lpm.2011.10.028","volume":"41","author":"M Malina","year":"2012","unstructured":"Malina M, Roumenina LT, Seeman T, Le Quintrec M, Dragon-Durey MA, Schaefer F, et al. Genetics of hemolytic uremic syndromes. Presse Med. 2012;41(3 Pt 2):e105\u201314.","journal-title":"Presse Med"},{"issue":"8","key":"1549_CR20","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1681\/ASN.2006080811","volume":"18","author":"AL Sellier-Leclerc","year":"2007","unstructured":"Sellier-Leclerc AL, Fremeaux-Bacchi V, Dragon-Durey MA, Macher MA, Niaudet P, Guest G, et al. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2007;18(8):2392\u2013400.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"1549_CR21","doi-asserted-by":"publisher","first-page":"50","DOI":"10.2215\/CJN.06440616","volume":"12","author":"F Fakhouri","year":"2017","unstructured":"Fakhouri F, Fila M, Provot F, Delmas Y, Barbet C, Chatelet V, et al. Pathogenic variants in complement genes and risk of atypical hemolytic uremic syndrome relapse after eculizumab discontinuation. Clin J Am Soc Nephrol. 2017;12(1):50\u20139.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"1549_CR22","doi-asserted-by":"publisher","first-page":"e10208","DOI":"10.1371\/journal.pone.0010208","volume":"5","author":"P Coppo","year":"2010","unstructured":"Coppo P, Schwarzinger M, Buffet M, Wynckel A, Clabault K, Presne C, et al. Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience. PLoS One. 2010;5(4):e10208.","journal-title":"PLoS One"},{"issue":"1","key":"1549_CR23","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s40560-014-0061-4","volume":"2","author":"S Kurosawa","year":"2014","unstructured":"Kurosawa S, Stearns-Kurosawa DJ. Complement, thrombotic microangiopathy and disseminated intravascular coagulation. J Intensive Care. 2014;2(1):65.","journal-title":"J Intensive Care"},{"issue":"8","key":"1549_CR24","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1056\/NEJMra020528","volume":"347","author":"JL Moake","year":"2002","unstructured":"Moake JL. Thrombotic microangiopathies. N Engl J Med. 2002;347(8):589\u2013600.","journal-title":"N Engl J Med"},{"issue":"5","key":"1549_CR25","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1038\/ki.2013.373","volume":"85","author":"A Sinha","year":"2014","unstructured":"Sinha A, Gulati A, Saini S, Blanc C, Gupta A, Gurjar BS, et al. Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children. Kidney Int. 2014;85(5):1151\u201360.","journal-title":"Kidney Int"},{"issue":"3","key":"1549_CR26","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.kint.2016.10.005","volume":"91","author":"TH Goodship","year":"2017","unstructured":"Goodship TH, Cook HT, Fakhouri F, Fervenza FC, Fremeaux-Bacchi V, Kavanagh D, et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) Controversies Conference. Kidney Int. 2017;91(3):539\u201351.","journal-title":"Kidney Int"},{"issue":"1","key":"1549_CR27","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s10157-013-0911-8","volume":"18","author":"T Sawai","year":"2014","unstructured":"Sawai T, Nangaku M, Ashida A, Fujimaru R, Hataya H, Hidaka Y, et al. Diagnostic criteria for atypical hemolytic uremic syndrome proposed by the Joint Committee of the Japanese Society of Nephrology and the Japan Pediatric Society. Clin Exp Nephrol. 2014;18(1):4\u20139.","journal-title":"Clin Exp Nephrol"}],"updated-by":[{"DOI":"10.1007\/s10157-019-01728-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,4,23]],"date-time":"2019-04-23T00:00:00Z","timestamp":1555977600000}}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10157-018-1549-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-018-1549-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-018-1549-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T19:47:57Z","timestamp":1600285677000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10157-018-1549-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,6]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["1549"],"URL":"https:\/\/doi.org\/10.1007\/s10157-018-1549-3","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s10157-019-01728-3","asserted-by":"object"}]},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,6]]},"assertion":[{"value":"1 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2019","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original article can be found online","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2019","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original article can be found online","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Yoshihiro Fujimura is a recipient of patent royalty for ADAMTS13 activity-ELISA kits from Alfressa, Honoraria: Hideki\u2028Kato and Masaomi Nangaku from Alexion Pharma, Hideo Wada from IL Japan and Alexion Pharma, and Masanori Matsumoto from Asahi Kasei Pharma and Alexion Pharma, Research funding: Masanori Matsumoto from Bayer Yakuhin, Chugai Pharmaceutical, and Asahi Kasei Pharma, Subsidies or Donations: Masaomi Nangaku from Alexion Pharma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approval: all procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee at which the studies were conducted (IRB approval number G10029) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}